News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Japan’s Eisai Inc. to Delay Parkinson’s Drug Submission
October 30, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Oct 30 (Reuters) - Japanese drug maker Eisai Co Ltd (4523.T: Quote, Profile, Research) said on Tuesday it would delay submission of its U.S. and European applications for a drug candidate to treat Parkinson's disease.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Asia
MORE ON THIS TOPIC
Stomach cancer
Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study
November 18, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Bets More Than $2.6B for South Korea Biotech’s Bispecific Antibody Platform
November 17, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
November 14, 2025
·
1 min read
·
Dan Samorodnitsky
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
November 14, 2025
·
2 min read
·
Tristan Manalac
